The anti-interleukin agent romilkimab showed significant benefits on skin fibrosis among patients with systemic sclerosis in a phase II trial, researchers reported. At week 24, the least squares mean ...

FDA grants Breakthrough Therapy status to NVS's ianalumab for Sjogren's disease with plans for global filings starting in ...

Patients with SSc were linked to an increased risk for hematological malignancies, specifically B-cell malignancies.

In addition to PH, columnist Jolie Lizana faces a possible scleroderma diagnosis, as coexisting conditions continue to ...

Brenig Therapeutics, Inc. (Brenig), a clinical-stage biotechnology company advancing small-molecule therapies for neurodegenerative diseases, today announced the initiation of a first-in-human (FIH) ...

Mycophenolate mofetil treatment in patients with limited cutaneous systemic sclerosis is linked to a reduced need for escalation of vasoactive or vasodilator therapies for vascular complications.

A new University of Toronto-led study has discovered a possible biomarker linked to multiple sclerosis (MS) disease progression that could help identify patients most likely to benefit from new drugs.

Gilbert Gee and Annie Ro depict systemic racism as the hidden base of an iceberg 10 (see illustration in online appendix exhibit 1). 11 The iceberg’s visible part represents the overt racism that ...

Exclusive: Scientists uncovered biological strands using artificial intelligence and hope discovery will revolutionise treatment Scientists have discovered two new subtypes of multiple sclerosis with ...

Nutritional issues such as ARFID are highly prevalent among patients with SSc and can lead to poor outcomes and other ...

Objective Sjögren’s is a chronic systemic autoimmune disease characterised by dryness symptoms (eyes, mouth, skin), alongside ...